PTPRN
Receptor-type tyrosine-protein phosphatase-like N
Also known as: IA-2, ICA512, PTPRN_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q16849
- Gene
- PTPRN
- Ensembl
- ENSG00000054356
- Chromosome
- 2
- Canonical length
- 979 aa
- Protein class
- Disease related genes, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Endoplasmic reticulum
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region, a single transmembrane region, and a single catalytic domain, and thus represents a receptor-type PTP. This PTP was found to be an autoantigen that is reactive with insulin-dependent diabetes mellitus (IDDM) patient sera, and thus may be a potential target of autoimmunity in diabetes mellitus. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Dec 2010]
Canonical amino-acid sequenceUniProt
979 residues, UniProt reviewed canonical sequence.
>Q16849|PTPRN
1 MRRPRRPGGL GGSGGLRLLL CLLLLSSRPG GCSAVSAHGC LFDRRLCSHL EVCIQDGLFG
61 QCQVGVGQAR PLLQVTSPVL QRLQGVLRQL MSQGLSWHDD LTQYVISQEM ERIPRLRPPE
121 PRPRDRSGLA PKRPGPAGEL LLQDIPTGSA PAAQHRLPQP PVGKGGAGAS SSLSPLQAEL
181 LPPLLEHLLL PPQPPHPSLS YEPALLQPYL FHQFGSRDGS RVSEGSPGMV SVGPLPKAEA
241 PALFSRTASK GIFGDHPGHS YGDLPGPSPA QLFQDSGLLY LAQELPAPSR ARVPRLPEQG
301 SSSRAEDSPE GYEKEGLGDR GEKPASPAVQ PDAALQRLAA VLAGYGVELR QLTPEQLSTL
361 LTLLQLLPKG AGRNPGGVVN VGADIKKTME GPVEGRDTAE LPARTSPMPG HPTASPTSSE
421 VQQVPSPVSS EPPKAARPPV TPVLLEKKSP LGQSQPTVAG QPSARPAAEE YGYIVTDQKP
481 LSLAAGVKLL EILAEHVHMS SGSFINISVV GPALTFRIRH NEQNLSLADV TQQAGLVKSE
541 LEAQTGLQIL QTGVGQREEA AAVLPQTAHS TSPMRSVLLT LVALAGVAGL LVALAVALCV
601 RQHARQQDKE RLAALGPEGA HGDTTFEYQD LCRQHMATKS LFNRAEGPPE PSRVSSVSSQ
661 FSDAAQASPS SHSSTPSWCE EPAQANMDIS TGHMILAYME DHLRNRDRLA KEWQALCAYQ
721 AEPNTCATAQ GEGNIKKNRH PDFLPYDHAR IKLKVESSPS RSDYINASPI IEHDPRMPAY
781 IATQGPLSHT IADFWQMVWE SGCTVIVMLT PLVEDGVKQC DRYWPDEGAS LYHVYEVNLV
841 SEHIWCEDFL VRSFYLKNVQ TQETRTLTQF HFLSWPAEGT PASTRPLLDF RRKVNKCYRG
901 RSCPIIVHCS DGAGRTGTYI LIDMVLNRMA KGVKEIDIAA TLEHVRDQRP GLVRSKDQFE
961 FALTAVAEEV NAILKALPQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PTPRN can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 178 nTPM
Expression across tissuesHPA
Tissue
- pituitary gland: 178 nTPM
- hypothalamus: 157 nTPM
- cerebral cortex: 142 nTPM
- basal ganglia: 117 nTPM
- hippocampal formation: 90 nTPM
- amygdala: 77 nTPM
Single-cell type
- pancreatic islet cells: 618 nCPM
- somatotrophs: 163 nCPM
- gonadotrophs: 125 nCPM
- lactotrophs: 112 nCPM
- other brain neurons: 112 nCPM
- brain inhibitory neurons: 82 nCPM
Immune cell
- total PBMC: 0.6 nTPM
- T-reg: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
Brain region
- hypothalamus: 554 nTPM
- pons: 352 nTPM
- cerebral cortex: 336 nTPM
- hippocampal formation: 249 nTPM
- amygdala: 244 nTPM
- basal ganglia: 243 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PTPRN.
Disease | ImmuneIEDB
Conditions an epitope on PTPRN was assayed in.
- type 1 diabetes mellitus B and T cell
- type 2 diabetes mellitus T cell
- latent autoimmune diabetes in adults B cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against PTPRN are reported. Each links to that disease's full target list.
- Diabetes Mellitus, Type 1 312
- Diabetes Mellitus, Type 2 54
- Polyendocrinopathies, Autoimmune 5
- Thyroiditis, Autoimmune 5
- Celiac Disease 4
- Obesity 4
- Insulin Resistance 3
- Stiff-Person Syndrome 3
Showing 8 of 16 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for PTPRN from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
386 publications
- Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop.
1998 · Diabetes · RCR 9.2 · 368 citations - Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers.
1997 · Diabetes · RCR 8.7 · 365 citations - Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies.
2003 · JAMA · RCR 7.9 · 342 citations - Timing of initial cereal exposure in infancy and risk of islet autoimmunity.
2003 · JAMA · RCR 7.8 · 345 citations - Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group.
1998 · J Clin Invest · RCR 5.5 · 239 citations
Show 20 more of 386 total
- Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes.
2000 · Diabetes · RCR 5.5 · 269 citations - Patterns of β-cell autoantibody appearance and genetic associations during the first years of life.
2013 · Diabetes · RCR 5.1 · 170 citations - Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.
2016 · Diabetes Care · RCR 5.1 · 146 citations - Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies.
1995 · J Immunol · RCR 4.8 · 209 citations - ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules.
1996 · EMBO J · RCR 4.6 · 225 citations - High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes.
2007 · Diabetes Care · RCR 4.5 · 189 citations - Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes.
2011 · Diabet Med · RCR 4.5 · 160 citations - Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics.
2004 · Diabetes · RCR 4.5 · 214 citations - IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus.
1996 · Proc Natl Acad Sci U S A · RCR 4.4 · 187 citations - Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young.
2011 · Diabetes Care · RCR 4.2 · 166 citations - Targeted next-generation sequencing reveals MODY in up to 6.5% of antibody-negative diabetes cases listed in the Norwegian Childhood Diabetes Registry.
2017 · Diabetologia · RCR 4.2 · 102 citations - Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes.
2003 · J Clin Endocrinol Metab · RCR 3.9 · 174 citations - In utero dietary exposures and risk of islet autoimmunity in children.
2003 · Diabetes Care · RCR 3.9 · 149 citations - IA-2 antibodies--a sensitive marker of IDDM with clinical onset in childhood and adolescence. Childhood Diabetes in Finland Study Group.
1998 · Diabetologia · RCR 3.8 · 152 citations - Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients.
2017 · Diabetes Care · RCR 3.8 · 105 citations - Clinical, autoimmune, and genetic characteristics of very young children with type 1 diabetes. Childhood Diabetes in Finland (DiMe) Study Group.
1999 · Diabetes Care · RCR 3.7 · 138 citations - ICA512 autoantibody radioassay.
1995 · Diabetes · RCR 3.6 · 129 citations - Type 1 diabetes and autoimmunity.
2014 · Clin Pediatr Endocrinol · RCR 3.5 · 100 citations - Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation.
2008 · PLoS One · RCR 3.5 · 150 citations - Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I.
2004 · J Clin Endocrinol Metab · RCR 3.5 · 163 citations
Reference: B cellIEDB
6 publications
- Enterovirus infection may induce humoral immune response reacting with islet cell autoantigens in humans.
2003 · J Med Virol · RCR 0.7 · 32 citations - Humoral responses to islet antigen-2 and zinc transporter 8 are attenuated in patients carrying HLA-A*24 alleles at the onset of type 1 diabetes.
2013 · Diabetes · RCR 0.5 · 20 citations - Autoantibodies and associated T-cell responses to determinants within the 831-860 region of the autoantigen IA-2 in Type 1 diabetes.
2009 · J Autoimmun · RCR 0.5 · 23 citations - Immunoreactivities Against Different Tyrosine-Phosphatase 2 (IA-2)(256-760) Protein Domains Characterize Distinct Phenotypes in Subjects With LADA.
2022 · Front Endocrinol (Lausanne) · RCR 0.3 · 3 citations - Fine mapping of diabetes-associated IA-2 specific autoantibodies.
2003 · J Autoimmun · RCR 0.2 · 12 citations
Show 1 more
- Radiobinding assay for detecting autoantibodies to single epitopes.
2008 · J Immunol Methods · RCR 0.1 · 4 citations
Reference: T cellIEDB
8 publications
- Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4.
1999 · J Clin Invest · RCR 2.2 · 115 citations - CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes.
2014 · J Autoimmun · RCR 2.1 · 73 citations - Chromogranin A is a T cell antigen in human type 1 diabetes.
2014 · J Autoimmun · RCR 2 · 68 citations - Peptides Derived From Insulin Granule Proteins Are Targeted by CD8+ T Cells Across MHC Class I Restrictions in Humans and NOD Mice.
2020 · Diabetes · RCR 1.9 · 45 citations - Recognition of HLA class I-restricted beta-cell epitopes in type 1 diabetes.
2006 · Diabetes · RCR 1.9 · 87 citations
Show 3 more
- IFN-gamma and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes.
2010 · Diabetologia · RCR 1 · 49 citations - T-cell lines reactive to an immunodominant epitope of the tyrosine phosphatase-like autoantigen IA-2 in type 1 diabetes.
2000 · Diabetes · RCR 1 · 58 citations - HLA-DR4-associated T and B cell responses to specific determinants on the IA-2 autoantigen in type 1 diabetes.
2014 · J Immunol · RCR 0.4 · 14 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.58
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.6
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- dense core granule maturation
- insulin secretion
- insulin secretion involved in cellular response to glucose stimulus
- luteinization
- positive regulation of transcription by RNA polymerase II
- positive regulation of type B pancreatic cell proliferation
- regulation of secretion
- response to reactive oxygen species
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Tyrosine-specific protein phosphatase, PTPase domain
- Tyrosine-specific protein phosphatases domain
- Protein-tyrosine phosphatase, catalytic
- Protein-tyrosine phosphatase, active site
- Protein-tyrosine phosphatase receptor IA-2 ectodomain
- Protein-tyrosine phosphatase-like
- RESP18 domain
- Receptor-type tyrosine-protein phosphatase-like N/N2
- Protein-tyrosine phosphatase receptor IA-2, ectodomain superfamily
- Protein-tyrosine phosphatase
- Protein-tyrosine phosphatase receptor IA-2
- RESP18 domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PTPRN in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PTPRN as an antibody target. Whether an autoantibody or antibody against PTPRN could matter depends on whether native PTPRN is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PTPRN is annotated at the cell surface, where native PTPRN is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Source-annotated serology context
The source annotations explicitly mention antibody, autoantibody, autoantigen, or autoimmune context. This is biological context, not study-specific reactivity.
- This PTP was found to be an autoantigen that is reactive with insulin-dependent diabetes mellitus (IDDM) patient sera, and thus may be a potential target of autoimmunity in diabetes mellitus.
Loading the interactive Seroatlas protein explorer...